渤健Biogen （BIIB） 2019年企业责任报告「NASDAQ」.pdf

《渤健Biogen （BIIB） 2019年企业责任报告「NASDAQ」.pdf》由会员分享，可在线阅读，更多相关《渤健Biogen （BIIB） 2019年企业责任报告「NASDAQ」.pdf（106页珍藏版）》请在三个皮匠报告上搜索。

1、2019 Year in ReviewOur Commitment to Corporate ResponsibilityBiogen ScientistsGene Therapy Analytical DevelopmentCambridge,MATransduction and transgene expression in retina cellsMicroscopic image byIris Wang,Ophthalmology Research UnitTable of contentsPURPOSE ANDPERFORMANCEPIONEERINGSCIENCE02OUR PEO

2、PLEPATIENTSCOMMUNITY ANDENVIRONMENTREPORTINGPurpose and Performance01Pioneering ScienceOur PeoplePatientsCommunity and EnvironmentReporting0203040506Our purposePURPOSE ANDPERFORMANCEPIONEERINGSCIENCE03OUR PEOPLEPATIENTSCOMMUNITY ANDENVIRONMENTREPORTINGCaring Deeply.Working Fearlessly.Changing Lives.

3、These words are not just a philosophy we live by but are words that defne every action we take.A deep unwavering commitment to the patients we serve,the employees that make us who we are and the environment and communities where we live and work.At Biogen,we are not afraid to go where others wont.Wi

4、th our expertise and technology,we have pioneered drug discovery in neuroscience and we remain committed to expanding access to new potential treatments.Our goal is to make a meaningful difference in the lives of people suffering from devastating neurological and neurodegenerative conditions.Not bec

5、ause we can,but because we must.In addition to serving patients,we are passionate about our commitment to our employees,the environment and our local communities.These commitments not only refect who we are and our dedication to changing lives,but also to changing the world we live in for the better

6、.2019 was also marked by changing developments for aducanumab,an investigational treatment for early Alzheimers disease.In October 2019,together with our collaboration partner Eisai Co.,Ltd.(Eisai),we announced plans to pursue regulatory approval for aducanumab in the U.S.This decision was based on